TEK/TIE2 Recombinant Rabbit mAb (S-3846-54)

TEK protein, also known as Tie2 (Tyrosine kinase with Ig and EGF homology domains 2), is a receptor tyrosine kinase expressed on vascular endothelial cells and belongs to the Tie receptor family, playing an irreplaceable core role in embryonic vascular development and adult vascular homeostasis maintenance. Its specific ligands are members of the angiopoietin family (Angiopoietins). Among them, Ang1 acts as an agonist that, upon binding to TEK, induces receptor dimerization and phosphorylation, activating downstream PI3K-AKT signaling pathways to promote endothelial cell survival, migration, adhesion, and pericyte recruitment, thereby stabilizing mature blood vessels and suppressing vascular permeability. In contrast, Ang2, under specific conditions (such as hypoxia or inflammatory stimulation), functions as an antagonist or partial agonist, interfering with sustained TEK signaling and rendering vessels responsive to pro-angiogenic factors like VEGF, thereby creating conditions for vascular sprouting and remodeling. This "stabilization/remodeling" switch function of TEK makes it a pivotal player in vascular biology—its gene mutations lead to hereditary vascular disorders such as familial venous malformations and primary congenital glaucoma. In the field of oncology, aberrant TEK signaling is closely associated with abnormal tumor vasculature, hyperpermeability, and immune evasion. Consequently, small-molecule inhibitors or neutralizing antibodies targeting the TEK/Angiopoietin axis, such as Trebananib, have been extensively evaluated in clinical trials across various solid tumors (including ovarian cancer and renal cancer) to explore their potential in inhibiting tumor angiogenesis and sensitizing tumors to chemotherapy.